Data protection Impressum

Healthcare

ONWARD Medical has secured EUR 40.6 million through an accelerated bookbuild offering led by a EUR 25 million investment from EQT Life Sciences, extending the company's cash runway into the first quarter of 2028.

ONWARD Medical raises EUR 40 million to extend ARC therapy commercialization

20 April 2026

Four life sciences projects were recognized at BIND – BioInnovation Day 2026, held at CHUV Lausanne on 1 April 2026, as the region's flagship academic innovation showcase drew 340 participants from academia, healthcare, industry, and investment.

BIND 2026 highlights Western Switzerland’s life sciences innovation pipeline

14 April 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (March 2026)

1 April 2026

Switzerland has ranked first in the Henley Opportunity Index 2026, scoring 86 out of 100 across six structural drivers of long-term prosperity, further cementing its standing as the world's leading destination for talent, investment, and quality of life.

Switzerland tops the 2026 Henley Opportunity Index

30 March 2026

Global in vitro diagnostics leader bioMérieux has invested over CHF 1 million in Geneva-based scale-up Plair, whose RAPID-C+ system is setting a new standard for real-time viable particle monitoring in pharmaceutical cleanrooms.

bioMérieux invests in Plair to advance environmental monitoring in pharma

30 March 2026

The Foundation for Innovation and Technology (FIT) has awarded Tech Seed loans totaling CHF 250,000 to three Western Switzerland start-ups developing solutions in therapeutic gaming, pregnancy monitoring, and sports protection.

FIT awards Tech Seed loans to Diverssity, MoleSense, and Performance MouthGuard

23 March 2026

Harnessing the promise of emerging quantum technologies, Western Switzerland is shaping up to be a pivotal region in this transformative field.

Quantum technologies in Western Switzerland

HeroSupport, a spin-off from the University Hospitals of Geneva, has obtained CE Mark certification for VENUS SHELL, a personalized 3D-printed breast immobilization system for prone radiotherapy.

HeroSupport receives CE Mark for its VENUS SHELL radiotherapy device

10 March 2026

Lausanne-based Polares Medical has closed an oversubscribed USD 50 million Series C financing round to advance clinical studies of its MRace Posterior Leaflet Replacement system for mitral regurgitation across the US, Europe, and Australia.

Polares Medical raises USD 50 million to advance its mitral valve replacement system

9 March 2026

Alithea Genomics has completed its seed financing round with an additional CHF 3 million, bringing the total to CHF 6.9 million, to accelerate the commercialization of its large-scale RNA sequencing platforms for drug screening and toxicology.

Alithea Genomics raises CHF 6.9 million to industrialize RNA sequencing

9 March 2026

1 2 3 4 5 6 7 8 9 … 24